DE69815872D1 - Verwendung von d-methionin zur verminderung der toxizität von ototoxischen arzneimitteln und geräusch - Google Patents

Verwendung von d-methionin zur verminderung der toxizität von ototoxischen arzneimitteln und geräusch

Info

Publication number
DE69815872D1
DE69815872D1 DE69815872T DE69815872T DE69815872D1 DE 69815872 D1 DE69815872 D1 DE 69815872D1 DE 69815872 T DE69815872 T DE 69815872T DE 69815872 T DE69815872 T DE 69815872T DE 69815872 D1 DE69815872 D1 DE 69815872D1
Authority
DE
Germany
Prior art keywords
noise
methods
platinum
radiation
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69815872T
Other languages
English (en)
Other versions
DE69815872T2 (de
Inventor
C Campbell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Southern Illinois University System
Original Assignee
Southern Illinois University System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Illinois University System filed Critical Southern Illinois University System
Application granted granted Critical
Publication of DE69815872D1 publication Critical patent/DE69815872D1/de
Publication of DE69815872T2 publication Critical patent/DE69815872T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69815872T 1997-10-02 1998-04-08 Verwendung von d-methionin zur verminderung der toxizität von ototoxischen arzneimitteln und geräusch Expired - Lifetime DE69815872T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/942,845 US6187817B1 (en) 1996-10-03 1997-10-02 Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
US942845 1997-10-02
PCT/US1998/006960 WO1999017765A1 (en) 1997-10-02 1998-04-08 Use of d-methionine to reduce the toxicity of ototoxic drugs, noise, and radiation

Publications (2)

Publication Number Publication Date
DE69815872D1 true DE69815872D1 (de) 2003-07-31
DE69815872T2 DE69815872T2 (de) 2004-07-08

Family

ID=25478684

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69815872T Expired - Lifetime DE69815872T2 (de) 1997-10-02 1998-04-08 Verwendung von d-methionin zur verminderung der toxizität von ototoxischen arzneimitteln und geräusch

Country Status (10)

Country Link
US (2) US6187817B1 (de)
EP (1) EP1019036B1 (de)
JP (1) JP2001518499A (de)
AT (1) ATE243511T1 (de)
AU (1) AU753039B2 (de)
CA (1) CA2303901C (de)
DE (1) DE69815872T2 (de)
ES (1) ES2202834T3 (de)
PT (1) PT1019036E (de)
WO (1) WO1999017765A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7071230B2 (en) * 1997-10-02 2006-07-04 Board Of Trustees Of Southern Illinois University Therapeutic use of D-methionine to reduce the toxicity of noise
US6187817B1 (en) * 1996-10-03 2001-02-13 Southern Illinois University School Of Medicine Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
US20040082509A1 (en) * 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2004096256A1 (en) * 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
PL370867A1 (en) * 2001-09-24 2005-05-30 Tosk, Inc. Reduced toxicity cisplatin formulations and methods for using the same
US7700134B2 (en) * 2002-01-17 2010-04-20 The Regents Of The University Of Michigan Prevention of cisplatin induced deafness
US20050101534A1 (en) * 2002-11-13 2005-05-12 Sepracor, Inc. Compositions and methods for treating or preventing hearing impairment
US20050090551A1 (en) * 2003-10-27 2005-04-28 Board Of Trustees Of Southern Illinois University Therapeutic use of methionine for the treatment or prevention of mucositis
US20060058390A1 (en) * 2004-09-14 2006-03-16 Molecular Therapeutics, Inc. D-methionine formulation with improved biopharmaceutical properties
DK1886112T3 (da) 2005-04-06 2014-09-08 Univ St Louis Fremgangsmåde til Måling af metabolismen af neuralt afledte biomolekyler in vivo
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
EP1928410A2 (de) 2005-09-29 2008-06-11 Nektar Therapeutics Antibiotische formulierungen, einheitsdosen, kits und verfahren
US20070105782A1 (en) * 2005-10-07 2007-05-10 Board Of Trustees Of Southern Illinois University Protectant Combinations for Reducing Toxicities
US7951845B2 (en) * 2006-01-19 2011-05-31 The Regents Of The University Of Michigan Composition and method of treating hearing loss
US9889156B2 (en) 2006-01-19 2018-02-13 The Regents Of The University Of Michigan Method for treating noise-induced hearing loss (NIHL)
US10238599B2 (en) 2006-01-19 2019-03-26 The Regents Of The University Of Michigan Composition and method for treating congenital cytomegalovirus induced hearing loss
USRE46372E1 (en) 2006-01-19 2017-04-25 The Regents Of The Univerity Of Michigan Method for treating hearing loss
US8927528B2 (en) 2006-01-19 2015-01-06 The Regents Of The University Of Michigan Composition for treating hearing loss
US9770433B2 (en) 2006-01-19 2017-09-26 The Regents Of The University Of Michigan Composition and method for treating tinnitus
US9919008B2 (en) 2006-01-19 2018-03-20 The Regents Of The University Of Michigan Method for treating age-related hearing loss (ARHL)
US8338397B2 (en) * 2006-01-19 2012-12-25 The Regents Of The University Of Michigan Composition and method of treating side effects from antibiotic treatment
US20090155390A1 (en) * 2006-01-19 2009-06-18 Miller Josef M Composition and method of treating temporary and permanent hearing loss
EP2001460A4 (de) * 2006-03-28 2011-01-12 Novus Int Inc Zusammensetzungen zur förderung des haarwachstums
US20090111736A1 (en) * 2007-10-29 2009-04-30 Sri International Orally-Absorbed Solid Dose Formulation for Vancomycin
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
JP5457813B2 (ja) * 2009-12-16 2014-04-02 ルネサスエレクトロニクス株式会社 Ａｄｐｌｌ回路、半導体装置及び携帯情報機器
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2013178763A1 (en) * 2012-05-30 2013-12-05 Sensorion Methods for treating vestibulotoxicity
EA201501080A1 (ru) 2013-06-26 2016-07-29 Ксижен Инфлемейшн Лтд. Новое применение обладающих способностью проникать в клетку пептидных ингибиторов пути трансдукции сигнала jnk для лечения различных заболеваний
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
KR102502356B1 (ko) 2014-09-30 2023-02-21 워싱턴 유니버시티 타우 (tau) 활동 계측

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2732400A (en) 1956-01-24 Method of preparing methionine
US4426372A (en) 1980-08-08 1984-01-17 Regents Of The University Of Minnesota Inhibition of undesired effects of platinum(II) compounds
US5002755A (en) 1988-02-18 1991-03-26 Vanderbilt University Method of controlling nephrotoxicity of anti-tumor plaintum compounds
US5292773A (en) 1990-02-14 1994-03-08 Hirsch Gerald P Treating aids and HIV infection with methionine
DE69322251T2 (de) 1992-09-04 1999-07-29 Fuji Chem Ind Co Ltd Medizinische zusammensetzung
US6187817B1 (en) * 1996-10-03 2001-02-13 Southern Illinois University School Of Medicine Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds

Also Published As

Publication number Publication date
DE69815872T2 (de) 2004-07-08
EP1019036A1 (de) 2000-07-19
US6265386B1 (en) 2001-07-24
ATE243511T1 (de) 2003-07-15
CA2303901C (en) 2008-09-09
JP2001518499A (ja) 2001-10-16
EP1019036B1 (de) 2003-06-25
CA2303901A1 (en) 1999-04-15
US6187817B1 (en) 2001-02-13
AU6956898A (en) 1999-04-27
WO1999017765A1 (en) 1999-04-15
AU753039B2 (en) 2002-10-03
PT1019036E (pt) 2003-11-28
ES2202834T3 (es) 2004-04-01

Similar Documents

Publication Publication Date Title
DE69815872D1 (de) Verwendung von d-methionin zur verminderung der toxizität von ototoxischen arzneimitteln und geräusch
CA2294247A1 (en) Antioxidant enhancement of therapy for hyperproliferative conditions
MX9703621A (es) Nuevos derivados aminoacidos con actividad mejorada para la resistencia a drogas multiples.
EE03523B1 (et) Fenantridiinid, neid sisaldavad ravimid ja nende kasutamine
DE69533551D1 (de) Camptothecin arzneimittelkombinationen mit verringerten nebenwirkungen
HK1123741A1 (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders (dextromethorphan)(quinidine)
MY117526A (en) N-(3-benzofuranyl)urea-derivatives
HRP920632A2 (en) Oral composition for the treatment of inflammatory l deseases
DK0393575T3 (da) Præparater til behandling af neoplasia indeholdende antineoplastisk middel og beskyttelsesmiddel til formindskelse af bivirkninger
TW362971B (en) Pharmaceutical composition and kit for treating cancer by conjunctive therapy with 2&#39;-halomethylidene derivatives and a S-phase or M-phase specific anti
TR200002860T2 (tr) Bir antiviral benzimidazol terkibin yeni kristal formları.
TR199903214T2 (xx) Bir antit�m�r maddesi ve bir hidroksimik asit t�revini ihtiva eden, antit�m�r etkinli�i artt�r�lm�� ve yan etkileri d���r�lm�� farmas�tik bile�im.
IL133824A0 (en) Tetrazole derivatives, medicaments containing same and use thereof
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
CA2368618A1 (en) Method of enhancing the efficacy of anti-tumor agents
GR3026602T3 (en) Morphogen-induced liver regeneration.
ATE536178T1 (de) Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis
JPS5767518A (en) Radiosensitizing agent or agent for increasing effect of radiomimetic substance
DE69735722D1 (de) D-methionin zur reduzierung der toxizität von platin-enthaltenden antitumor verbindungen
ATE199641T1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
EP1575531A4 (de) Therapien für chronische entzündliche demyelinierende polyneuropathi mit interferon-beta
CA2234936A1 (en) Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
ATE22282T1 (de) Pentacycloundecan derivate, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen.
DK1023314T3 (da) Galdesyredsalte af metaller med fysiologisk virkning og anvendelsen deraf ved terapi
EP1390027A4 (de) Zusammensetzung mit demethylcantharidin in kombination mit platinhaltigen antikrebsmitteln und ihre verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition